Skip to main content
Clinical Trials/ISRCTN11853110
ISRCTN11853110
Completed
Phase 3

Randomised controlled trial of the clinical and cost effectiveness of Alpha-Stim AID cranial electrotherapy stimulation (CES) in treatment seeking patients with moderate severity depressive episodes in primary care

niversity of Nottingham0 sites236 target enrollmentAugust 14, 2020

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Nottingham
Enrollment
236
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35379314/ (added 05/10/2022) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36724796/ (added 02/02/2023)

Registry
who.int
Start Date
August 14, 2020
End Date
May 31, 2022
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Nottingham

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged \=16 years
  • 2\. Diagnosis of current Major Depressive Episode (MDE)
  • 3\. A Score of \=10 or 9\-item self\-rated Personal Health Questionnaire (PHQ\-9\)
  • 4\. Have either been offered the option of anti\-depressant medication or prescribed antidepressant medication for a minimum of 6 weeks in the last 3 months
  • 5\. Capable of giving oral and written informed consent to the study, and this consent is confirmed by the researcher at eligibility screening and baseline assessment
  • 6\. Agrees to return Alpha\-Stim equipment at the end of the study and not to purchase this equipment privately during the study

Exclusion Criteria

  • 1\. A score of \=20 on the PHQ\-9
  • 2\) Neurological conditions e.g. brain neoplasm, cerebrovascular events, epilepsy, neurodegenerative disorders, and prior brain surgery
  • 3\. Requiring urgent clinical care such as having persistent suicidal ideation, self\-harm or suicidal intent.
  • 4\. Known to be pregnant
  • 5\. Implantation with a pacemaker or an implantable cardioverter device (ICD)
  • 6\. Major unstable medical illness requiring further investigation or treatment
  • 7\. A diagnosis of current substance use disorder or dependence, dementia, eating disorder, bipolar disorder or nonaffective psychosis because the use of CES treatment would otherwise require additional supervision or is associated with additional risk e.g. of mania in bipolar disorder
  • 8\. Completed and benefitted from/responded to psychological treatment for depression in the last 3 months or planning to commence psychological treatment in the next 6 months
  • 9\. Involved with any other clinical trial at the time of consent or 6 months prior

Outcomes

Primary Outcomes

Not specified

Similar Trials